160 related articles for article (PubMed ID: 25588741)
21. [Expression of OCT4 protein in bladder cancer and its clinicopathological implications].
Zhao P; Liu C; Xu K; Zheng S; Li H; Xu Y; Xu A; Li B; Huang P
Nan Fang Yi Ke Da Xue Xue Bao; 2012 May; 32(5):643-6. PubMed ID: 22588915
[TBL] [Abstract][Full Text] [Related]
22. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.
Post DE; Van Meir EG
Oncogene; 2003 Apr; 22(14):2065-72. PubMed ID: 12687009
[TBL] [Abstract][Full Text] [Related]
23. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
24. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia inducible factor 2α/insulin-like growth factor receptor signal loop supports the proliferation and Oct-4 maintenance of mouse germline stem cells.
Huang YH; Lin MH; Wang PC; Wu YC; Chiang HL; Wang YL; Chang JH; Huang YK; Gu SY; Ho HN; Ling TY
Mol Hum Reprod; 2014 Jun; 20(6):526-37. PubMed ID: 24598112
[TBL] [Abstract][Full Text] [Related]
26. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
27. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells.
Xue M; Li X; Chen W
Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells.
Cui XY; Skretting G; Jing Y; Sun H; Sandset PM; Sun L
Blood Cells Mol Dis; 2013 Oct; 51(3):177-84. PubMed ID: 23725749
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.
Ioachim E; Michael M; Salmas M; Michael MM; Stavropoulos NE; Malamou-Mitsi V
Urol Int; 2006; 77(3):255-63. PubMed ID: 17033215
[TBL] [Abstract][Full Text] [Related]
31. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
[TBL] [Abstract][Full Text] [Related]
32. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Chang CC; Shieh GS; Wu P; Lin CC; Shiau AL; Wu CL
Cancer Res; 2008 Aug; 68(15):6281-91. PubMed ID: 18676852
[TBL] [Abstract][Full Text] [Related]
33. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
[TBL] [Abstract][Full Text] [Related]
34. Expression and significance of Oct4 in bladder cancer.
Xu K; Zhu Z; Zeng F
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):675-7. PubMed ID: 18231740
[TBL] [Abstract][Full Text] [Related]
35. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.
Covello KL; Kehler J; Yu H; Gordan JD; Arsham AM; Hu CJ; Labosky PA; Simon MC; Keith B
Genes Dev; 2006 Mar; 20(5):557-70. PubMed ID: 16510872
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
37. Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus.
Moon CY; Choi JW; Kasala D; Jung SJ; Kim SW; Yun CO
Biomaterials; 2015 Feb; 41():53-68. PubMed ID: 25522965
[TBL] [Abstract][Full Text] [Related]
38. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.
Yang Y; Xu H; Shen J; Yang Y; Wu S; Xiao J; Xu Y; Liu XY; Chu L
Cell Death Dis; 2015 May; 6(5):e1760. PubMed ID: 25973680
[TBL] [Abstract][Full Text] [Related]
39. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection.
Aprelikova O; Wood M; Tackett S; Chandramouli GV; Barrett JC
Cancer Res; 2006 Jun; 66(11):5641-7. PubMed ID: 16740701
[TBL] [Abstract][Full Text] [Related]
40. Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus.
Hamada K; Zhang T; Desaki J; Nakashiro K; Itoh H; Tani K; Koyama Y; Hamakawa H
J Gene Med; 2010 Jun; 12(6):545-54. PubMed ID: 20527047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
